Linked Life Data

20669562

Source:http://linkedlifedata.com/resource/pubmed/id/20669562

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2010-7-30
pubmed:abstractText
Neuroendocrine tumors are rare but their incidence is increasing and might be underestimated. The prognosis is highly variable and depends on the tumor type, its location, metastatic status, and the degree of differentiation. The diagnosis relies primarily on imaging methods. Various investigations must be combined for accurate staging, prognostication and decision-making. Current management combines symptomatic treatment (with antisecretory drugs for example) and surgery, which must be as comprehensive as possible, even when metastases are present. Second-line treatment options include chemotherapy, embolization, chemoembolization and radio-frequency therapies. Upcoming targeted therapies and metabolic radiotherapy should improve these patients' prognosis.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0001-4079
pubmed:author
pubmed:issnType
Print
pubmed:volume
194
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
97-104; discussion 104-5
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
[New insights into neuroendocrine tumors: molecular biology, imaging and targeted therapies].
pubmed:affiliation
Pôle maladies métaboliques, médecine interne et soins de suite, CHU Angers, 4, rue Larrey, 49933 Angers cedex 9. virohmer@chu-angers.fr
pubmed:publicationType
Journal Article, English Abstract, Review